(PC) Williams v. Ogbuehi

District Court, E.D. California·Decided April 3, 2020·No. 1:19-cv-00855·Unknown

Opinion

7 UNITED STATES DISTRICT COURT

8 EASTERN DISTRICT OF CALIFORNIA

10 GERRY WILLIAMS, Case No. 1:19-cv-00855-EPG (PC)

11 Plaintiff, FINDINGS AND RECOMMENDATIONS, 12 v. RECOMMENDING THAT THIS ACTION BE DISMISSED FOR FAILURE TO STATE A 13 CLEMENT OGBUEHI, et al., CLAIM

14 Defendants. (ECF NO. 12) 15 OBJECTIONS, IF ANY, DUE WITHIN 16 TWENTY-ONE (21) DAYS

17 ORDER DIRECTING THE CLERK OF COURT TO ASSIGN A DISTRICT JUDGE 18 19 Gerry Williams (“Plaintiff”) is a state prisoner proceeding pro se and in forma pauperis 20 in this civil rights action filed pursuant to 42 U.S.C. § 1983. Plaintiff filed the complaint 21 commencing this action on June 19, 2019. (ECF No. 1). The Court screened Plaintiff’s 22 complaint, provided the relevant legal standards, and gave Plaintiff leave to amend. (ECF No. 23 11). Plaintiff filed a First Amended Complaint on November 8, 2019 (ECF No. 12), which is 24 before this Court for screening. 25 For the reasons set forth below, the Court recommends that this action be dismissed for 26 failure to state a claim. 27 Plaintiff has twenty-one days from the date of service of these findings and 28 recommendations to file his objections. 1 I. SCREENING REQUIREMENT 2 The Court is required to screen complaints brought by prisoners seeking relief against a 3 governmental entity or officer or employee of a governmental entity. 28 U.S.C. § 1915A(a). 4 The Court must dismiss a complaint or portion thereof if the prisoner has raised claims that are 5 legally “frivolous or malicious,” that fail to state a claim upon which relief may be granted, or 6 that seek monetary relief from a defendant who is immune from such relief. 28 U.S.C. 7 § 1915A(b)(1), (2). As Plaintiff is proceeding in forma pauperis (ECF No. 7), the Court may 8 also screen the complaint under 28 U.S.C. § 1915. “Notwithstanding any filing fee, or any 9 portion thereof, that may have been paid, the court shall dismiss the case at any time if the court 10 determines that the action or appeal fails to state a claim upon which relief may be granted.” 11 28 U.S.C. § 1915(e)(2)(B)(ii). 12 A complaint is required to contain “a short and plain statement of the claim showing 13 that the pleader is entitled to relief.” Fed. R. Civ. P. 8(a)(2). Detailed factual allegations are 14 not required, but “[t]hreadbare recitals of the elements of a cause of action, supported by mere 15 conclusory statements, do not suffice.” Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009) (citing Bell 16 Atlantic Corp. v. Twombly, 550 U.S. 544, 555 (2007)). Plaintiff must set forth “sufficient 17 factual matter, accepted as true, to ‘state a claim to relief that is plausible on its face.’” Id. 18 (quoting Twombly, 550 U.S. at 570). The mere possibility of misconduct falls short of meeting 19 this plausibility standard. Id. at 679. While a plaintiff’s allegations are taken as true, courts 20 “are not required to indulge unwarranted inferences.” Doe I v. Wal-Mart Stores, Inc., 572 F.3d 21 677, 681 (9th Cir. 2009) (internal quotation marks and citation omitted). Additionally, a 22 plaintiff’s legal conclusions are not accepted as true. Iqbal, 556 U.S. at 678. 23 Pleadings of pro se plaintiffs “must be held to less stringent standards than formal 24 pleadings drafted by lawyers.” Hebbe v. Pliler, 627 F.3d 338, 342 (9th Cir. 2010) (holding that 25 pro se complaints should continue to be liberally construed after Iqbal). 26 II. SUMMARY OF PLAINTIFF’S FIRST AMENDED COMPLAINT 27 Plaintiff’s First Amended Complaint alleges as follows: 28 In or about 2010, while housed at Pleasant Valley State Prison (“PVSP”), Plaintiff was 1 diagnosed with Hepatitis C (“Hep-C”). Hep-C requires interferon treatment. 2 Plaintiff was transferred to Kern Valley Sate Prison (“KVSP”) on April 12, 2012. 3 On April 4, 2013, Plaintiff requested a medical transfer from KVSP based on the fact 4 that Plaintiff suffers from Hep-C and should be receiving treatment. Plaintiff was evaluated on 5 February 11, 2013 by Doctor A. Manasrah, who documented that Plaintiff was Hep-C positive. 6 On October 17, Plaintiff submitted a “Health Care Service Request Form” stating that 7 he was experiencing excruciating pain in the upper right side, which he believed may be related 8 to Hep-C causing liver or kidney damage. 9 Plaintiff was evaluated by RN J. German on December 2, 2013, who recorded that 10 Plaintiff had a history of Hep-C. 11 For more than three years, Plaintiff complained to Defendant Wayne Ulit that he was 12 having excruciating pain in his upper right side and that he believed his Hep-C was getting 13 worse. Yet, Defendant Wayne Ulit stated that he would not give Plaintiff the treatment because 14 the medication is very expensive and Plaintiff had to be under 55 years old to receive the 15 treatment. 16 On or about November 29, 2016, Plaintiff was evaluated by Defendant Clement 17 Ogbuehi. Dr. Ogbuehi reviewed Plaintiff’s medical history and discovered that Plaintiff was 18 Hep-C positive. Plaintiff explained that he has been experiencing excruciating pain in the 19 upper right side for four or five years and has not received any treatment. Plaintiff explained 20 that there was a new drug that could cure Hep-C. Defendant Ogbuehi denied Plaintiff this new 21 medication and failed to provide Plaintiff any other type of treatment, due to the expensive cost 22 of the drug. 23 By the time Defendants Ulit and Ogbuehi decided to treat Plaintiff for Hep-C, Plaintiff 24 had contracted cirrhosis of the liver. 25 On July 3, 2017, Plaintiff filed a medical appeal requesting treatment of Harvoni 26 medication for Hep-C and cirrhosis of the liver. Plaintiff has been asking for treatment for 27 more than five years and has not received any type of treatment. 28 Plaintiff has had Hep-C for more than 18 years and has not received any type of 1 treatment. Defendants stated that Plaintiff’s Hep-C was undetectable. 2 Until fairly recently, the standard treatment regimen consisted of high doses of 3 interferon, a virus-fighter produced by white blood cells in combination with another drug, 4 Ribavirin. The drugs were effective in fewer than half the cases and could cause significant 5 side effects such as anemia, hair loss, flu-like symptoms, memory loss, and liver failure. 6 Adding a third drug to the package, Boceprevir, appeared to boost success rates somewhat, but 7 also increased the likelihood of side effects. 8 Starting in 2013, when Plaintiff requested treatment, the release of a new generation of 9 direct-acting antivirals, known as ADDs, offered new hope for Hep-C patients. The new drugs 10 are tailored to combat specific genotypes of the virus, and are more effective than interferon, 11 resulting in virtual cure in more than 90% of patients. 12 Plaintiff requested this new drug, Harvoni, which is a cure for Hep-C, prior to 13 contracting cirrhosis of the liver. Defendants Ulit and Ogbuehi refused to provide Plaintiff 14 with medications due to the cost. Now Plaintiff’s Hep-C has developed into cirrhosis of the 15 liver.

Free access — add to your briefcase to read the full text and ask questions with AI

(PC) Williams v. Ogbuehi, (E.D. Cal. 2020).

(PC) Williams v. Ogbuehi ((PC) Williams v. Ogbuehi) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Estelle v. Gamble
429 U.S. 97 (Supreme Court, 1976)
Chapman v. Houston Welfare Rights Organization
441 U.S. 600 (Supreme Court, 1979)
Baker v. McCollan
443 U.S. 137 (Supreme Court, 1979)
Graham v. Connor
490 U.S. 386 (Supreme Court, 1989)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Hebbe v. Pliler
627 F.3d 338 (Ninth Circuit, 2010)
Powell v. Alexander
391 F.3d 1 (First Circuit, 2004)
Hoffman v. Applicators Sales & Service, Inc.
439 F.3d 9 (First Circuit, 2006)
Francisco Sanchez v. Esso Standard Oil Co.
572 F.3d 1 (First Circuit, 2009)
Eric Sanchez v. Duane R. Vild
891 F.2d 240 (Ninth Circuit, 1989)
John C. McGuckin v. Dr. Smith John C. Medlen, Dr.
974 F.2d 1050 (Ninth Circuit, 1992)
Toguchi v. Soon Hwang Chung
391 F.3d 1051 (Ninth Circuit, 2004)
Marsh v. County of San Diego
680 F.3d 1148 (Ninth Circuit, 2012)
Harold Hall v. City of Los Angeles
697 F.3d 1059 (Ninth Circuit, 2012)